Satellite Symposium: The Road Ahead: CD30-targeted therapy in lymphoma
Dear colleagues and friends,
It is with great pleasure that I invite you to participate in our satellite forum entitled The Road Ahead: CD30-targeted therapy in lymphoma.
During the course of the interactive discussion we will address emerging treatment options for cutaneous lymphoma patients, focusing on CD30 as a therapeutic target.
There will be a session on the rationale for CD30 targeting in lymphoma, as well as in-depth looks at the clinical evidence & ongoing trials for CD30-targeting agents and at the changing landscape of CTCL management. There will also be a panel discussion including all faculty at which you will be able to ask any questions you have about CD3-targeted lymphoma treatment.
Rein Willemze from Leiden University Medical Center will highlight the general rationale for targeting CD30 in cutaneous lymphoma.
Timothy Illidge from the University of Manchester will then present the current clinical evidence and review ongoing trials of CD30-targeting agents.
Finally, I will discuss the changing landscape of CTCL management, and this will be followed by an interactive Q&A session in which you will be able to ask any questions you have about CD30-targeted lymphoma treatment.
We hope that you will enjoy this meeting, and that this will be an interesting opportunity for you to strengthen your expertise in CD30-targeted lymphoma treatment.
Warm regards,
Sean Whittaker